ArticleEmerging infectious diseases2021
Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global prevalence of COVID-19-induced acute respiratory distress syndrome: systematic review and meta-analysis.Systematic reviews · 2023Pooled it
- Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Inequalities and determinants of unmet need for SARS-CoV-2 testing in Ghana, Burkina Faso and Madagascar (2020 - 2021).Communications medicine · 2026Article
- Population-based cross-sectional seroprevalence study of SARS-CoV-2 infection in urban residential areas in Ghana.BMJ public health · 2025Article
- Distribution and determinants of COVID-19 seroprevalence in a hard-to-access health district in Mali.PLOS global public health · 2025Article
- SARS-CoV-2 seroprevalence in people living with HIV in South Sudan.IJID regions · 2024Article
- Transmissibility and severity of COVID-19 in a humanitarian setting: First few X investigation of cases and contacts in Juba, South Sudan, 2020.Influenza and other respiratory viruses · 2023Article
- Seroprevalence of SARS-CoV-2 antibodies in Republic of Congo, February 2022.Epidemiology and infection · 2023Article
- Estimation of epidemiological parameters and ascertainment rate from early transmission of COVID-19 across Africa.Royal Society open science · 2023Article
- Alternative epidemic indicators for COVID-19 in three settings with incomplete death registration systems.Science advances · 2023Article
- High seroprevalence of anti-SARS-CoV-2 antibodies in the capital of Chad.Journal of public health in Africa · 2022Article
- Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein.Scientific reports · 2022Article
- Comparison of COVID-19 Pandemic Waves in 10 Countries in Southern Africa, 2020-2021.Emerging infectious diseases · 2022Review
- Seroincidence of Enteric Fever, Juba, South Sudan.Emerging infectious diseases · 2022Article
- High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.BMC public health · 2022Article
- Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.IJID regions · 2022Article
- The COVID-19 pandemic in the African continent.BMC medicine · 2022Article
- SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan.Emerging infectious diseases · 2022Article
- COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the General Population of the Capital City Tunis.Diagnostics (Basel, Switzerland) · 2022Article
- Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar.BMC public health · 2022Article
Corrections and comments
- Update of
Authors and funding
26 authors.
Funding
Abstract
Relatively few coronavirus disease cases and deaths have been reported from sub-Saharan Africa, although the extent of its spread remains unclear. During August 10-September 11, 2020, we recruited 2,214 participants for a representative household-based cross-sectional serosurvey in Juba, South Sudan. We found 22.3% of participants had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain IgG titers above prepandemic levels. After accounting for waning antibody levels, age, and sex, we estimated that 38.3% (95% credible interval 31.8%-46.5%) of the population had been infected with SARS-CoV-2. At this rate, for each PCR-confirmed SARS-CoV-2 infection reported by the Ministry of Health, 103 (95% credible interval 86-126) infections would have been unreported, meaning SARS-CoV-2 has likely spread extensively within Juba. We also found differences in background reactivity in Juba compared with Boston, Massachusetts, USA, where the immunoassay was validated. Our findings underscore the need to validate serologic tests in sub-Saharan Africa populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.